Last year when the German pharmaceutical giant Bayer unveiled a $66 billion deal to buy Monsanto, the giant American agrichemical and biotechnology corporation, the plan provoked protests.

That opposition to the deal was played out again at Bayer's Annual General Meeting in Bonn, especially by shareholders who are angry about not getting an open vote on it.